Comparative Pharmacology
Head-to-head clinical analysis: MENOPUR versus OVIDREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENOPUR versus OVIDREL.
MENOPUR vs OVIDREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.
None Documented
None Documented
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
The terminal elimination half-life is approximately 30 hours (range 20-48 hours) in healthy adults. This supports a single-dose regimen for final follicular maturation in assisted reproductive technology.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Primarily renal, with approximately 10% of the administered dose excreted unchanged in urine within 24 hours. The remainder undergoes metabolic degradation in the kidneys and liver.
Category C
Category C
Gonadotropin
Gonadotropin